pTT5-hSDC1 Citations (3)

Originally described in: Targeting of heparanase-modified syndecan-1 by prosecretory mitogen lacritin requires conserved core GAGAL plus heparan and chondroitin sulfate as a novel hybrid binding site that enhances selectivity.
Zhang Y, Wang N, Raab RW, McKown RL, Irwin JA, Kwon I, van Kuppevelt TH, Laurie GW J Biol Chem. 2013 Apr 26;288(17):12090-101. doi: 10.1074/jbc.M112.422717. Epub 2013 Mar 15. PubMed Journal

---

Articles Citing pTT5-hSDC1

Articles
Syndecan-1 suppresses epithelial-mesenchymal transition and migration in human oral cancer cells. Wang X, He J, Zhao X, Qi T, Zhang T, Kong C. Oncol Rep. 2018 Apr;39(4):1835-1842. doi: 10.3892/or.2018.6271. Epub 2018 Feb 14. PubMed
A Single-Agent Dual-Specificity Targeting of FOLR1 and DR5 as an Effective Strategy for Ovarian Cancer. Shivange G, Urbanek K, Przanowski P, Perry JSA, Jones J, Haggart R, Kostka C, Patki T, Stelow E, Petrova Y, Llaneza D, Mayo M, Ravichandran KS, Landen CN, Bhatnagar S, Tushir-Singh J. Cancer Cell. 2018 Aug 13;34(2):331-345.e11. doi: 10.1016/j.ccell.2018.07.005. PubMed
Selection and structural characterization of anti-TREM2 scFvs that reduce levels of shed ectodomain. Szykowska A, Chen Y, Smith TB, Preger C, Yang J, Qian D, Mukhopadhyay SM, Wigren E, Neame SJ, Graslund S, Persson H, Atkinson PJ, Di Daniel E, Mead E, Wang J, Davis JB, Burgess-Brown NA, Bullock AN. Structure. 2021 Nov 4;29(11):1241-1252.e5. doi: 10.1016/j.str.2021.06.010. Epub 2021 Jul 6. PubMed

If you have published an article using this material, please email us at to have your article added to this page.